Free Trial

Akoya Biosciences (AKYA) Stock Price, News & Analysis

+0.33 (+16.75%)
(As of 05/28/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.16 million shs
Average Volume
265,665 shs
Market Capitalization
$113.60 million
P/E Ratio
Dividend Yield
Price Target

Akoya Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
238.5% Upside
$7.79 Price Target
Short Interest
5.26% of Float Sold Short
Dividend Strength
News Sentiment
0.82mentions of Akoya Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$74,325 Sold Last Quarter
Proj. Earnings Growth
From ($0.91) to ($0.51) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

531st out of 931 stocks

Analytical Instruments Industry

15th out of 30 stocks

AKYA stock logo

About Akoya Biosciences Stock (NASDAQ:AKYA)

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

AKYA Stock Price History

AKYA Stock News Headlines

Piper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)
Akoya Biosciences CEO sells $37k worth of shares
Akoya Biosciences Inc (AKYA)
Q4 2023 Akoya Biosciences Inc Earnings Call
Recap: Akoya Biosciences Q4 Earnings
See More Headlines
Receive AKYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Analytical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$96.63 million
Book Value
$1.10 per share


Free Float
Market Cap
$113.60 million
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Brian McKelligon (Age 55)
    President, CEO & Director
    Comp: $854.99k
  • Mr. John Frederick Ek (Age 48)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $496.76k
  • Dr. Frederic G. Pla Ph.D. (Age 65)
    Chief Operating Officer
    Comp: $581.23k
  • Priyam Shah
    Senior Director of Business Development & Investor Relations Strategy
  • Ms. Jennifer Kamocsay (Age 53)
    General Counsel
  • Dr. Niro Ramachandran Ph.D. (Age 49)
    Chief Business Officer
    Comp: $298.18k
  • Dr. Pascal Bamford Ph.D.
    Senior Vice President, Research & Development and Laboratory Operations
  • Mr. Rob C. Hart CFA
    J.D., Secretary

AKYA Stock Analysis - Frequently Asked Questions

Should I buy or sell Akoya Biosciences stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AKYA shares.
View AKYA analyst ratings
or view top-rated stocks.

What is Akoya Biosciences' stock price target for 2024?

8 analysts have issued twelve-month price targets for Akoya Biosciences' stock. Their AKYA share price targets range from $6.00 to $10.00. On average, they anticipate the company's share price to reach $7.79 in the next year. This suggests a possible upside of 238.5% from the stock's current price.
View analysts price targets for AKYA
or view top-rated stocks among Wall Street analysts.

How have AKYA shares performed in 2024?

Akoya Biosciences' stock was trading at $4.88 at the beginning of the year. Since then, AKYA stock has decreased by 52.9% and is now trading at $2.30.
View the best growth stocks for 2024 here

Are investors shorting Akoya Biosciences?

Akoya Biosciences saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,160,000 shares, an increase of 11.5% from the April 30th total of 1,040,000 shares. Based on an average trading volume of 276,300 shares, the short-interest ratio is presently 4.2 days. Approximately 5.3% of the shares of the stock are short sold.
View Akoya Biosciences' Short Interest

When is Akoya Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our AKYA earnings forecast

How were Akoya Biosciences' earnings last quarter?

Akoya Biosciences, Inc. (NASDAQ:AKYA) issued its earnings results on Monday, March, 4th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.05. The business earned $26.49 million during the quarter, compared to the consensus estimate of $26.12 million. Akoya Biosciences had a negative trailing twelve-month return on equity of 111.80% and a negative net margin of 72.68%. During the same period in the prior year, the firm posted ($0.50) EPS.

What guidance has Akoya Biosciences issued on next quarter's earnings?

Akoya Biosciences issued an update on its FY 2024 earnings guidance on Monday, May, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $104.0 million-$112.0 million, compared to the consensus revenue estimate of $115.8 million.

When did Akoya Biosciences IPO?

Akoya Biosciences (AKYA) raised $125 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 6,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity acted as the underwriters for the IPO.

Who are Akoya Biosciences' major shareholders?

Akoya Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.95%), Silvercrest Asset Management Group LLC (1.18%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Mckelligon, Frederic Pla, Garry PhD Nolan, John Frederick Ek, Joseph Driscoll, Matthew Winkler, Niro PhD Ramachandran and Robert G Shepler.
View institutional ownership trends

How do I buy shares of Akoya Biosciences?

Shares of AKYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKYA) was last updated on 5/29/2024 by Staff

From Our Partners